- Home
- JFR vs SNDX Comparison
JFR vs SNDX Comparison
Compare JFR & SNDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JFR
- SNDX
- Stock Information
- Founded
- JFR 2004
- SNDX 2005
- Country
- JFR United States
- SNDX United States
- Employees
- JFR N/A
- SNDX N/A
- Industry
- JFR Trusts Except Educational Religious and Charitable
- SNDX Biotechnology: Pharmaceutical Preparations
- Sector
- JFR Finance
- SNDX Health Care
- Exchange
- JFR Nasdaq
- SNDX Nasdaq
- Market Cap
- JFR 1.1B
- SNDX 1.1B
- IPO Year
- JFR N/A
- SNDX 2016
- Fundamental
- Price
- JFR $8.42
- SNDX $16.32
- Analyst Decision
- JFR
- SNDX Strong Buy
- Analyst Count
- JFR 0
- SNDX 10
- Target Price
- JFR N/A
- SNDX $37.50
- AVG Volume (30 Days)
- JFR 621.7K
- SNDX 3.0M
- Earning Date
- JFR 01-01-0001
- SNDX 08-04-2025
- Dividend Yield
- JFR 11.31%
- SNDX N/A
- EPS Growth
- JFR N/A
- SNDX N/A
- EPS
- JFR N/A
- SNDX N/A
- Revenue
- JFR N/A
- SNDX $77,933,000.00
- Revenue This Year
- JFR N/A
- SNDX $585.73
- Revenue Next Year
- JFR N/A
- SNDX $94.17
- P/E Ratio
- JFR N/A
- SNDX N/A
- Revenue Growth
- JFR N/A
- SNDX 2126.66
- 52 Week Low
- JFR $7.61
- SNDX $8.58
- 52 Week High
- JFR $8.82
- SNDX $22.50
- Technical
- Relative Strength Index (RSI)
- JFR 50.40
- SNDX 75.31
- Support Level
- JFR $8.39
- SNDX $15.29
- Resistance Level
- JFR $8.53
- SNDX $16.43
- Average True Range (ATR)
- JFR 0.05
- SNDX 0.78
- MACD
- JFR -0.00
- SNDX 0.09
- Stochastic Oscillator
- JFR 50.00
- SNDX 82.10
About JFR Nuveen Floating Rate Income Fund
Nuveen Floating Rate Income Fund is a diversified closed-end management investment company. Its investment objective is to achieve a high level of current income, consistent with the preservation of capital. It invests in adjustable-rate U.S. dollar-denominated secured Senior Loans.
About SNDX Syndax Pharmaceuticals Inc.
Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.